Sucampo's new Phase III lubiprostone trial excludes patients on methadone
This article was originally published in Scrip
Sucampo Pharmaceuticals has begun a third Phase III clinical study with its gastrointestinal product lubiprostone for the management of opioid-induced bowel dysfunction (OBD) in patients with chronic non-cancer pain.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.